Massimo Terzolo researcher
Terzolo, Massimo
VIAF ID: 4728159764110108170005 (Personal)
Permalink: http://viaf.org/viaf/4728159764110108170005
Preferred Forms
- 100 0 _ ‡a Massimo Terzolo ‡c researcher
- 100 1 _ ‡a Terzolo, Massimo
- 100 1 _ ‡a Terzolo, Massimo
4xx's: Alternate Name Forms (1)
Works
Title | Sources |
---|---|
CYP2W1 is highly expressed in adrenal glands and is positively associated with the response to mitotane in adrenocortical carcinoma. | |
Cytotoxic Effect of Trabectedin In Human Adrenocortical Carcinoma Cell Lines and Primary Cells | |
Definition of an optimal strategy to evaluate and follow-up adrenal incidentalomas: time for further research. | |
Differential responses of serum and salivary interleukin-6 to acute strenuous exercise. | |
Doppler echocardiographic patterns in patients with acromegaly | |
Effects of Germline CYP2W1*6 and CYP2B6*6 Single Nucleotide Polymorphisms on Mitotane Treatment in Adrenocortical Carcinoma: A Multicenter ENSAT Study | |
Efficacy of the EDP-M Scheme Plus Adjunctive Surgery in the Management of Patients with Advanced Adrenocortical Carcinoma: The Brescia Experience | |
End-stage renal failure due to amyloidosis and recurrent fever on dialysis--is there a link? | |
Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial | |
Evaluation of the effectiveness of midnight serum cortisol in the diagnostic procedures for Cushing's syndrome | |
Exogenous melatonin enhances the TRH-induced prolactin release in normally cycling women: a sex-specific effect. | |
Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study | |
GH and IGF-I excess control contributes to blood pressure control: results of an observational, retrospective, multicentre study in 105 hypertensive acromegalic patients on hypertensive treatment | |
Growth hormone (GH) responses to GH-releasing hormone alone or combined with arginine in patients with adrenal incidentaloma: evidence for enhanced somatostatinergic tone | |
Growth hormone values after an oral glucose load do not add clinically useful information in patients with acromegaly on long-term somatostatin receptor ligand treatment. | |
Immunohistochemical assessment of Ki-67 in the differential diagnosis of adrenocortical tumors | |
Increased osteoprotegerin levels in Cushing's syndrome are associated with an adverse cardiovascular risk profile. | |
Influence of the CYP2B6 polymorphism on the pharmacokinetics of mitotane | |
Insulin resistance is not coupled with defective insulin secretion in primary hyperparathyroidism. | |
Involvement of 27-Hydroxycholesterol in Mitotane Action on Adrenocortical Carcinoma | |
Ketoconazole treatment in Cushing's disease. Effect on the circadian profile of plasma ACTH and cortisol | |
Laboratory differentiation of Cushing's syndrome | |
Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma | |
The limited value of the desmopressin test in the diagnostic approach to Cushing's syndrome. | |
Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study | |
Long-term follow-up in adrenal incidentalomas: an Italian multicenter study | |
Low dehydroepiandrosterone sulfate (DHEA-S) level is not a good predictor of hormonal activity in nonselected patients with incidentally detected tumors | |
Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer | |
Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection. | |
Management of adrenal cancer: a 2013 update | |
Management of adrenocortical carcinoma: a consensus statement of the Italian Society of Endocrinology (SIE). | |
Matrix metalloproteinase type 2 expression in malignant adrenocortical tumors: Diagnostic and prognostic significance in a series of 50 adrenocortical carcinomas | |
May an altered hypothalamo-pituitary-adrenal axis contribute to cortical bone damage in primary hyperparathyroidism? | |
Merits and pitfalls of mifepristone in Cushing's syndrome. | |
Metronomic chemotherapy may be active in heavily pre-treated patients with metastatic adreno-cortical carcinoma. | |
MHC2TA single nucleotide polymorphism and genetic risk for autoimmune adrenal insufficiency | |
MicroRNA expression patterns in adrenocortical carcinoma variants and clinical pathologic correlations | |
Midnight serum cortisol as a marker of increased cardiovascular risk in patients with a clinically inapparent adrenal adenoma | |
Mitotane reduces human and mouse ACTH-secreting pituitary cell viability and function | |
Mitotane Therapy in Adrenocortical Cancer Induces CYP3A4 and Inhibits 5α-Reductase, Explaining the Need for Personalized Glucocorticoid and Androgen Replacement | |
Molecular Mechanisms of Mitotane Action in Adrenocortical Cancer Based on In Vitro Studies | |
Myxoid adrenocortical adenoma with a pseudoglandular pattern | |
A new simple HPLC method for measuring mitotane and its two principal metabolites Tests in animals and mitotane-treated patients. | |
Non-functioning pituitary adenoma database: a useful resource to improve the clinical management of pituitary tumors | |
Oncocytic adrenocortical tumors: diagnostic algorithm and mitochondrial DNA profile in 27 cases. | |
OR29-2 Mild Autonomous Cortisol Excess (MACE) in Adrenal Incidentalomas - Metabolic Risk Profile and Urinary Steroid Metabolome Analysis in 1208 Prospectively Recruited Patients | |
Plasma concentrations of o,p'DDD, o,p'DDA, and o,p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study | |
Prevalence of adrenal carcinoma among incidentally discovered adrenal masses. A retrospective study from 1989 to 1994. Gruppo Piemontese Incidentalomi Surrenalici | |
The prevalence of colonic polyps in acromegaly: a colonoscopic and pathological study in 103 patients | |
Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study. | |
Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer. | |
Prognostic significance of disordered calcium metabolism in hormone-refractory prostate cancer patients with metastatic bone disease. | |
Progression of renal failure without proteinuria in a patient with type 1 diabetes | |
Prolactinoma in a diabetic dialysis patient with erectile dysfunction: a difficult differential diagnosis | |
Recovery of Adrenal Insufficiency Is Frequent After Adjuvant Mitotane Therapy in Patients with Adrenocortical Carcinoma | |
Relationship between blood pressure and glucose tolerance in acromegaly. | |
The reticulin algorithm for adrenocortical tumor diagnosis: a multicentric validation study on 245 unpublished cases. | |
Retrospective evaluation of the outcome of open versus laparoscopic adrenalectomy for stage I and II adrenocortical cancer | |
Ribonucleotide reductase large subunit (RRM1) gene expression may predict efficacy of adjuvant mitotane in adrenocortical cancer | |
RRM1 modulates mitotane activity in adrenal cancer cells interfering with its metabolization | |
Screening of Cushing's syndrome in outpatients with type 2 diabetes: results of a prospective multicentric study in Italy | |
Secondary hypoadrenalism | |
Serum levels of bone Gla protein (osteocalcin, BGP) and carboxyterminal propeptide of type I procollagen (PICP) in acromegaly: effects of long-term octreotide treatment | |
Serum markers of bone and collagen turnover in patients with Cushing's syndrome and in subjects with adrenal incidentalomas. | |
Sorafenib may induce hypophosphatemia through a fibroblast growth factor-23 (FGF23)-independent mechanism | |
Strategies for managing ACTH dependent mineralocorticoid excess induced by abiraterone | |
Therapeutic concentrations of mitotane (o,p'-DDD) inhibit thyrotroph cell viability and TSH expression and secretion in a mouse cell line model | |
THERAPY OF ENDOCRINE DISEASE: Improvement of cardiovascular risk factors after adrenalectomy in patients with adrenal tumors and subclinical Cushing's syndrome: a systematic review and meta-analysis | |
Topoisomerase 2α and thymidylate synthase expression in adrenocortical cancer | |
Unwanted Hormonal and Metabolic Effects of Postoperative Adjuvant Mitotane Treatment for Adrenocortical Cancer | |
Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors | |
Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study | |
What is the role of ultrasonography in the follow-up of adrenal incidentalomas? The Gruppo Piemontese Incidentalomi Surrenalici |